R Squared Ltd Purchases 17,105 Shares of Cerus Corporation $CERS

R Squared Ltd lifted its position in shares of Cerus Corporation (NASDAQ:CERS) by 44.3% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 55,760 shares of the biotechnology company’s stock after purchasing an additional 17,105 shares during the quarter. R Squared Ltd’s holdings in Cerus were worth $79,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in CERS. AQR Capital Management LLC boosted its position in shares of Cerus by 291.6% during the first quarter. AQR Capital Management LLC now owns 1,429,062 shares of the biotechnology company’s stock valued at $1,986,000 after purchasing an additional 1,064,133 shares in the last quarter. Acadian Asset Management LLC boosted its position in shares of Cerus by 112.5% during the first quarter. Acadian Asset Management LLC now owns 1,898,621 shares of the biotechnology company’s stock valued at $2,637,000 after purchasing an additional 1,005,079 shares in the last quarter. Nuveen LLC bought a new stake in shares of Cerus during the first quarter valued at approximately $643,000. Millennium Management LLC boosted its position in shares of Cerus by 12.0% during the first quarter. Millennium Management LLC now owns 3,222,327 shares of the biotechnology company’s stock valued at $4,479,000 after purchasing an additional 344,395 shares in the last quarter. Finally, US Bancorp DE bought a new stake in shares of Cerus during the first quarter valued at approximately $236,000. 78.37% of the stock is currently owned by institutional investors.

Cerus Trading Up 1.3%

Cerus stock opened at $1.53 on Monday. The company has a current ratio of 2.00, a quick ratio of 1.35 and a debt-to-equity ratio of 1.01. The business’s fifty day simple moving average is $1.42 and its two-hundred day simple moving average is $1.37. Cerus Corporation has a 12 month low of $1.12 and a 12 month high of $2.24. The company has a market capitalization of $293.30 million, a price-to-earnings ratio of -15.30 and a beta of 1.70.

Cerus (NASDAQ:CERS) last posted its quarterly earnings results on Tuesday, August 5th. The biotechnology company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.01). Cerus had a negative return on equity of 33.77% and a negative net margin of 9.81%.The business had revenue of $60.10 million during the quarter, compared to analysts’ expectations of $51.80 million. Cerus has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Cerus Corporation will post -0.08 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cerus in a research report on Friday. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $4.00.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.